Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | FBP1 | P09467 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19009121 | 0.83 | NPC1 (0.36) | G6PDPOLBGAANPC1RAB9A | |
| SCHEMBL8699062 | 0.79 | FBP1 (0.41) | NPC1RAB9ATDP1FBP1ALDH1A1 | |
| SCHEMBL1404270 | 0.77 | G6PD (0.42) | G6PDPOLBGAANPC1RAB9A | |
| SCHEMBL8696553 | 0.77 | ALDH1A1 (0.44) | NPC1RAB9ATDP1HTR2AFBP1 | |
| SCHEMBL14617615 | 0.76 | G6PD (0.45) | G6PDPOLBGAANPC1RAB9A | |
| SCHEMBL8697830 | 0.73 | KMT2A (0.41) | GAATDP1FBP1ALDH1A1KMT2A | |
| SCHEMBL566832 | 0.72 | NPC1 (0.45) | G6PDPOLBGAANPC1RAB9A | |
| SCHEMBL13924679 | 0.72 | NPC1 (0.45) | G6PDPOLBGAANPC1RAB9A | |
| SCHEMBL8704050 | 0.71 | MAPT (0.40) | POLBNPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL8697540 | 0.71 | G6PD (0.43) | G6PDGAAALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077694-B1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | RENOVIS INC (US) | 2004-07-21 | — | — | EP | claimed |
| US-6258852-B1 | NITRONE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2001-07-10 | — | — | US | claimed |
| EP-1077694-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | claimed |
| US-6083989-A | ADMINISTERING TO THE PATIENT SUFFERING FROM INFLAMMATORY BOWL MOVEMENT AN N-SUBSTITUTED ARYL NITRON COMPOUND OR SALT | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | claimed |
| WO-1999059576-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| US-7485684-B2 | Functionalization of living rubbery polymers with nitrones | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070004869-A1 | Functionalization of living rubbery polymers with nitrones | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| EP-1739098-A2 | Functionalization of living rubbery polymers with nitrones | The Goodyear Tire & Rubber Company (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7125934-B1 | Functionalization of living rubbery polymers with nitrones | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1077694-B1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | RENOVIS INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6762322-B1 | CYCLIZING IMINE GROUP TO OXAZIRIDINE RING USING PEROXYSULFATE OXIDIZING AGENT AND REARRANGING TO OXIME FUNCTIONALITY | GOODYEAR TIRE & RUBBER COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20040122225-A1 | PREPARATION OF NITRONE DERIVATIVES | THE GOODYEAR TIRE & RUBBER COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-20020052447-A1 | Rubber-containing sytrenic resin and process for producing the same | DAICEL CHEMICAL INDUSTRIES, LTD. | 2002-05-02 | — | — | US | disclosed |
| US-6333381-B1 | MORPHOLOGY AND THE PARTICLE SIZE OF RUBBER PARTICLES DISPERSED IN A STYRENIC RESIN ARE CONTROLLABLE; IMPROVING THE IMPACT RESISTANCE; SURFACE GLOSS; GRAFT POLYMERS; | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6258852-B1 | NITRONE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1077694-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6083989-A | ADMINISTERING TO THE PATIENT SUFFERING FROM INFLAMMATORY BOWL MOVEMENT AN N-SUBSTITUTED ARYL NITRON COMPOUND OR SALT | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| CN-1254722-A | Styrene resin containing rubber and preparing process thereof | DAICEL CHEM (JP) | 2000-05-31 | — | — | CN | disclosed |
| EP-1002812-A1 | Rubber-containing styrenic resin and process for producing the same | Daicel Chemical Industries, Ltd. (JP) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999059576-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122225-A1 | PREPARATION OF NITRONE DERIVATIVES | NOX5, NDUFS5, NDUFS8 | G6PD 297/4885POLB 335/4885GAA 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.